Last updated: September 8, 2026
The dexbrompheniramine maleate and pseudoephedrine sulfate combination is a mature, low-growth oral decongestant and antihistamine product historically sold as Drixoral Cold and Allergy. Its commercial decline reflects product withdrawal, manufacturing and supply constraints, retailer controls on pseudoephedrine, and substitution by newer antihistamines and combination cold medicines. The active ingredients have no meaningful remaining patent exclusivity, and the product has limited prospects for material revenue expansion without a differentiated reformulation or new brand strategy.
What is dexbrompheniramine maleate and pseudoephedrine sulfate?
The combination pairs a first-generation antihistamine with a systemic decongestant.
| Attribute |
Dexbrompheniramine maleate/pseudoephedrine sulfate |
| Antihistamine |
Dexbrompheniramine maleate |
| Decongestant |
Pseudoephedrine sulfate |
| Historical brand |
Drixoral Cold and Allergy |
| Typical extended-release strength |
6 mg dexbrompheniramine maleate/120 mg pseudoephedrine sulfate |
| Dosage form |
Extended-release oral tablet |
| Primary uses |
Nasal congestion, runny nose, sneezing, and allergy or cold symptoms |
| Regulatory category |
Legacy prescription and OTC-style combination product history |
| Current commercial position |
Mature, limited-availability product with low visibility |
| Biosimilar exposure |
None |
Dexbrompheniramine is the active dextrorotatory isomer of brompheniramine. It is sedating and has anticholinergic effects. Pseudoephedrine constricts nasal blood vessels and reduces congestion but is subject to federal retail controls in the United States because it can be diverted for illicit methamphetamine production.[1]
The combination competes against oral antihistamines, intranasal corticosteroids, phenylephrine products, standalone pseudoephedrine products, and newer branded allergy medicines.
What was the commercial history of Drixoral?
Drixoral was a long-standing cold and allergy brand associated with Schering-Plough. Its core product used an extended-release formulation intended to provide approximately 12 hours of symptom relief. The brand was later affected by corporate consolidation, product availability problems, and a declining market for older sedating antihistamines.
Drixoral’s commercial trajectory can be summarized as follows:
| Period |
Market development |
Financial effect |
| Pre-2000s |
Established cold and allergy brand |
Recurring but mature revenue |
| 2000s |
Increased competition from loratadine, cetirizine, and intranasal therapies |
Share erosion |
| Mid-to-late 2000s |
Product availability and manufacturing disruption |
Revenue deterioration |
| Post-Schering-Plough consolidation |
Reduced standalone brand visibility |
Lower promotional support |
| 2010s |
Retail pseudoephedrine controls and category substitution |
Continued contraction |
| Current market |
Limited brand presence and no evident high-growth platform |
Minimal direct revenue opportunity |
Public companies generally do not report Drixoral revenue separately. Schering-Plough and later Merck reported broader prescription, consumer health, or franchise results rather than sales for the individual combination. As a result, a product-level revenue series cannot be established from public company filings.
What is the current FDA regulatory status?
The product’s regulatory status is more complex than that of a standard modern OTC monograph product.
FDA OTC monograph regulation covers certain categories of nonprescription drugs, but historical products may also have been marketed under legacy NDAs or other transitional regulatory pathways. Drixoral and related formulations have appeared in drug-labeling and regulatory databases, but commercial availability has not been consistent.
Pseudoephedrine remains legally marketable in the United States, subject to the Combat Methamphetamine Epidemic Act. Retail consumers generally must provide identification, and sellers must maintain transaction records and comply with monthly purchase limits.[1]
The FDA’s regulatory environment creates several commercial constraints:
- Retail placement is restricted because pseudoephedrine is generally sold behind the pharmacy counter.
- Sales volume is limited by federal and state purchase controls.
- State rules can impose stricter requirements than federal law.
- The product must compete with phenylephrine, despite FDA concerns regarding the effectiveness of oral phenylephrine as a nasal decongestant.
- Sedating antihistamine labeling limits appeal for daytime use and certain consumer groups.
What patents protect dexbrompheniramine and pseudoephedrine products?
The original composition, use, and extended-release patents associated with this product class are expired or commercially exhausted. Dexbrompheniramine and pseudoephedrine are long-established active ingredients, and the combination does not have the characteristics of a modern patent-protected specialty product.
Composition patents
Any early patents covering the active-ingredient combination or broad therapeutic use would have expired decades ago. No current composition patent is likely to prevent generic or private-label competition.
Formulation patents
The principal historical protection would have involved:
- Extended-release tablets
- Controlled dissolution of pseudoephedrine
- Stabilization of the antihistamine-decongestant combination
- Tablet manufacturing and release profiles
Even if later formulation patents once existed, their commercial value would be limited by age, generic formulation alternatives, and the absence of a large branded market.
Method-of-use patents
Method-of-use patents are not a meaningful source of current exclusivity. The product is used for conventional symptomatic relief rather than a narrowly defined disease indication or specialized patient population.
Orange Book status
The Orange Book is primarily relevant to approved prescription drugs and does not function as a complete patent database for OTC monograph products. A legacy NDA listing, if present, would not by itself establish meaningful current market exclusivity. The commercial protection for this combination is effectively based on brand recognition, distribution, formulation know-how, and regulatory execution rather than enforceable patent barriers.[2]
When does dexbrompheniramine and pseudoephedrine lose exclusivity?
The active ingredients have already lost patent exclusivity. The commercial exclusivity timeline is therefore historical rather than prospective.
| Exclusivity type |
Current position |
| Active-ingredient patent |
Expired |
| Combination patent |
Expired or commercially irrelevant |
| Extended-release formulation patent |
No apparent current barrier of material commercial value |
| Pediatric exclusivity |
None of commercial significance |
| Orphan-drug exclusivity |
Not applicable |
| New chemical entity exclusivity |
Not applicable to these legacy ingredients |
| Biosimilar exclusivity |
Not applicable |
| Market exclusivity |
No meaningful current exclusivity identified |
There is no conventional upcoming patent cliff because the cliff occurred years ago. Any future entrant would face a market-entry problem, not an exclusivity problem.
Are there Paragraph IV challenges or generic litigation?
A Paragraph IV challenge is unlikely to be commercially important for this product. Paragraph IV litigation is generally associated with a currently protected drug listed in the Orange Book. For a legacy dexbrompheniramine-pseudoephedrine combination with expired or immaterial patent protection, a generic manufacturer can ordinarily compete through the applicable abbreviated or OTC regulatory pathway without needing to attack a valuable remaining patent estate.
No major current patent litigation involving this combination is a central market factor. Historical disputes, if any, would be more likely to involve regulatory status, labeling, manufacturing, or product availability than a high-value patent contest.
How large is the addressable market?
The addressable market is part of the broader U.S. cough, cold, allergy, and nasal decongestant categories. The combination itself represents a narrow subsegment.
Demand is limited by several factors:
- Consumers have shifted toward nonsedating antihistamines such as loratadine, cetirizine, and fexofenadine.
- Intranasal corticosteroids are preferred for persistent allergic rhinitis.
- Pseudoephedrine’s purchase restrictions reduce convenience.
- First-generation antihistamines are less attractive for daytime use.
- Many consumers choose multi-symptom products with broader brand recognition.
- Clinicians and pharmacists often avoid sedating antihistamines in older adults because of anticholinergic risk.
The product still has a clinical rationale for consumers seeking both congestion and allergy relief in a single extended-release tablet. That rationale does not translate into strong growth because the category is mature and heavily substituted.
What is the financial trajectory?
The financial trajectory is best characterized as decline, fragmentation, and low standalone visibility.
Revenue exposure
No major pharmaceutical company currently reports material revenue from this specific active-ingredient combination. Historical sales were likely meaningful at the brand level during Drixoral’s stronger years, but they were not separately disclosed in a way that supports a reliable current valuation.
The combination’s economic value is more likely to arise from:
- Private-label or store-brand sales
- Licensing of legacy brand rights
- Contract manufacturing
- Portfolio bundling with other OTC products
- Retailer-specific cold and allergy programs
The product is unlikely to support a premium valuation based on patent rights alone.
Margin profile
Gross margins can be attractive for mature oral OTC products because active-ingredient costs are low and manufacturing processes are established. Net margins are pressured by:
- Retailer bargaining power
- Pharmacy-counter distribution
- Compliance costs
- Low advertising efficiency
- Inventory and supply-chain constraints
- Competition from inexpensive generic tablets
A relaunch would require brand investment, regulatory review, supply-chain qualification, and retailer distribution. Those costs could exceed the economic value of the mature product unless the sponsor obtains a strong brand position or a differentiated delivery format.
Which companies are competing with this combination?
Competition comes from several groups rather than one direct rival.
| Competitor group |
Examples |
Competitive advantage |
| Standalone antihistamines |
Claritin, Zyrtec, Allegra |
Nonsedating positioning |
| Intranasal therapies |
Flonase and store-brand equivalents |
Stronger allergy-focused treatment |
| Pseudoephedrine products |
Sudafed and generics |
Established decongestant brand recognition |
| Combination cold products |
Advil Cold & Sinus, Tylenol Cold products, Mucinex products |
Broad symptom coverage |
| Phenylephrine products |
Sudafed PE and private-label equivalents |
Easier retail access, although efficacy is disputed |
| Store brands |
Retailer-controlled allergy and cold products |
Lower price and shelf control |
The most direct substitutes are pseudoephedrine-antihistamine combinations and separate use of a nonsedating antihistamine with a decongestant.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest but not zero.
An extended-release product requires validated dissolution testing, consistent tablet compression, stability data, packaging controls, and compliance with FDA current good manufacturing practice requirements. Pseudoephedrine also creates supply-chain and recordkeeping obligations because of diversion controls.
The principal barriers are operational:
- Access to compliant pseudoephedrine supply
- Pharmacy-counter distribution
- State-level regulatory compliance
- Retailer acceptance
- Stable extended-release performance
- Consumer awareness
- Product liability and labeling management
These barriers can delay entry, but they do not create durable competitive protection comparable with a live pharmaceutical patent.
What generic launch risks exist?
A generic or private-label launch would face low legal risk but uncertain commercial returns.
Generic launch scenarios
| Scenario |
Likely result |
| Low-price immediate launch |
Rapid price competition and limited margin |
| Private-label retailer launch |
Better shelf access but retailer-controlled economics |
| Branded relaunch |
Higher revenue potential, higher marketing cost |
| Reformulated extended-release product |
Differentiation, but added development and regulatory expense |
| E-commerce-focused product |
Limited by pseudoephedrine controls and fulfillment rules |
| International launch |
Dependent on local decongestant regulation and product registration |
The most credible commercial strategy would be a low-cost private-label product or a reformulated allergy-and-congestion product with improved tolerability, packaging, or dosing convenience. A simple generic copy would have limited pricing power.
How strong is the patent estate?
The patent estate is weak for current commercial purposes.
| Patent-estate factor |
Assessment |
| Composition protection |
Weak or expired |
| Formulation protection |
Historical and likely expired |
| Method-of-use protection |
Minimal |
| Patent litigation leverage |
Low |
| Regulatory exclusivity |
None of material current value |
| Manufacturing know-how |
Moderate but replicable |
| Brand protection |
Dependent on trademark rights and consumer recognition |
| Commercial moat |
Limited |
The main defensible assets would be trademark rights, retailer relationships, manufacturing quality, and a differentiated formulation. Patent enforcement is unlikely to be the primary value driver.
What licensing deals and settlement agreements affect the product?
No current high-value licensing transaction or patent settlement is a major publicly recognized market driver for this combination. Historical brand ownership and commercialization rights changed through corporate transactions involving Schering-Plough and Merck, but those events were portfolio-level rather than product-specific.
The lack of a visible licensing or settlement pipeline reinforces the conclusion that this is a mature, low-priority asset rather than an active business-development target.
Key Takeaways
- Dexbrompheniramine maleate/pseudoephedrine sulfate is a legacy antihistamine-decongestant combination historically associated with Drixoral.
- The active ingredients and historical combination patents have no meaningful remaining exclusivity.
- FDA regulation of pseudoephedrine creates retail and supply-chain friction.
- The product has no biosimilar risk and little current Paragraph IV or patent-litigation significance.
- Revenue is not separately disclosed by major pharmaceutical companies and is likely limited today.
- Competition from nonsedating antihistamines, intranasal steroids, standalone pseudoephedrine, and private-label products has reduced the product’s market relevance.
- The strongest commercial opportunities are private-label distribution, licensing, or differentiated reformulation rather than patent-based commercialization.
- Manufacturing and regulatory compliance create operational barriers, but they do not establish a durable intellectual-property moat.
FAQs
Is Drixoral still available in the United States?
Availability has been inconsistent, and the historical brand does not have the market presence of major current allergy and cold brands. Retail and pharmacy inventories may vary by product format and jurisdiction.
Is dexbrompheniramine the same as brompheniramine?
No. Dexbrompheniramine is the dextrorotatory isomer of brompheniramine. Both are first-generation antihistamines, but they are distinct active ingredients for regulatory and labeling purposes.
Can a company launch a generic version of the combination?
A company may be able to enter through the applicable FDA regulatory pathway if it satisfies formulation, labeling, manufacturing, and pseudoephedrine-control requirements. The primary obstacle is commercial economics rather than patent exclusion.
Does pseudoephedrine require a prescription?
In the United States, pseudoephedrine is generally available without a prescription but is sold through pharmacy-counter controls. Buyers must comply with identification, purchase-limit, and recordkeeping requirements.
Is this combination a viable pharmaceutical licensing target?
It is more suitable for a low-cost OTC, private-label, or portfolio licensing transaction than for a conventional prescription-drug licensing deal. Value would depend on brand rights, distribution, supply reliability, and formulation differentiation.
References
- U.S. Drug Enforcement Administration. (n.d.). The Combat Methamphetamine Epidemic Act of 2005 and retail sales of pseudoephedrine. https://www.dea.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- U.S. Food and Drug Administration. (n.d.). Over-the-counter drug review and monograph system. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs
- U.S. National Library of Medicine. (n.d.). DailyMed: Current medication labeling. https://dailymed.nlm.nih.gov
- Merck & Co., Inc. (2009). Annual report. Merck & Co., Inc. https://www.merck.com/investor-relations/financial-information/annual-reports/
